Adjuvant chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment and following gemcitabine monotherapy for patients with transitional cell carcinoma of the urothelium

Minerva Urologica e Nefrologica

Volumn 61, Issue 3, 2009, Pages 249-256

  Ecke, T H ^a   Gerullis, H ^b   Bartel, P ^a   Koch, S ^a   Ruttloff, J ^a  

^a HELIOS Klinikum Bad Saarow   (Germany)

^b Lukaskrankenhaus GmbH   (Germany)

Author keywords

Chemotherapy, adjuvant; Cisplatin; Gemcitabine; Neoplasms; Paclitaxel; Urothelium

Indexed keywords

CISPLATIN; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FATIGUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; UROTHELIUM; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; KIDNEY NEOPLASMS; KIDNEY PELVIS; MALE; MIDDLE AGED; PACLITAXEL; RETROSPECTIVE STUDIES; URETERAL NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 74749099361     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Aben KK, Witjes JA, Schoenberg MP, Hulsbergen-van de Kaa C, Verbeek AL, Kiemeney LA. Familial aggregation of urothelial cell carcinoma. Int J Cancer 2002;41:89-106.
3. Sternberg CN, Marini L, Calabro F. Systemic chemotherapy of bladder cancer. In: Skinner DG, Syrigos KN eds. Bladder Cancer: Biology and Management. New York, NY: Oxford University Press; 1999. p. 299-315.
4. De Braud F, Maffezzini M, Vitale V. Bladder Cancer. Crit Rev Oncol Hematol 2002;41:89-106.
5. von der Maase H. Current and future perspectives in advanced bladder cancer: is there a new standard? Semin Oncol 2002;29 (Suppl 3):3-14.
6. Sternberg CN. Gemcitabine in bladder cancer. Semin Oncol 2000;27(Suppl 2):31-9.
7. Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelium carcinoma of the bladder: a cooperative group study. J Clin Oncol 1992;10:1066-73.
8. Soloway MS, Einstein A, Corder MP, Bonney W, Prout GR Jr, Coombs J. A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A National Bladder Cancer Collaborative Group A Study. Cancer 1983;52:767-72.
9. Scher HI, Shipley WU, Herr HW. Cancer of the Bladder. In: DeVita VTJr., Hellman S, Rosenberg SA eds. Cancer principles and practice of oncology. 5th edition. Philadelphia: Lippincott-Raven; 1997. p. 1300-22.
10. Yagoda A. Chemotherapy of urothelial tract tumors. Cancer 1987;60:574-85.
11. Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985;133:403-7.
12. Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N1 Herr HW et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 1989;64:2448-58.
13. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG et al. A prospective randomized trial comparing M-VAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8:1050-5.
14. von der Maase H, Hansen SW, Roberts JT, Ricci S, Dogliotti L, Oliver T et al Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J Clin Oncol 2000;18:3068-77.
15. McCaffrey JA, Hilton S, Mazumdar M. Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma. J Clin Oncol 1997;15:1853-7.
16. de Wit R, Kruit WH, Stoter G, de Boer M, Kerger J, Verweij J. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer: results of a phase II study in non-chemotherapy-pretreated patients. BrJ Cancer 1998;78:1342-5.
17. Papamichael D, Gallagher CJ, Oliver RTD, Johnson PW, WaxmanJ. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. BrJ Cancer 1997;75:606-7.
18. Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002;20:937-40.
19. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997;15:3394-8.
20. Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997; 15:3441-5.
21. Lorusso V, Pollera CF, Antimi M, Luporini G, Gridelli C, Frassineti GL et al. A Phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998;34:1208-12.
22. Gatzemeier U, Shepherd FA, Le Chevallier T, Weynants P, Cottier B, Groen HJ et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre extended phase II study. Eur J Cancer 1996;32;243-8.
23. Moore M. Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review. Cancer 1996;78(Suppl 3);633-8.
24. Shapiro JD, Milward MJ, Rischin D, Michael M, Walcher V, Francis PA et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996;63;89-93.
25. Bellmunt J, Guillem V, Paz-Ares L, Climent MA, González-Larriba JL, Carles J et al. Phase I/II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol 2000;18:3247-55.
26. Bellmunt J, Guillem V, Paz-Ares L, Climent MA, Gonzâlez-Larriba JL, CarlesJ et al. Pretreatment Prognostic Factors for Survival in Patients with Advanced Urothelial Tumors Treated in a Phase I/II Trial with Paclitaxel, Cisplatin, and Gemcitabine. Cancer 2002;95:751-7.
27. Ecke TH, Bartel P, Koch S, Ruttloff J, and Theissig F. Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Oncol Rep 2006;16:1381-8.
28. Hussain M, Vaishampayan U, Du W, Redman B, Smith DC. Combination carboplatin, paclitaxel and gemcitabine. Is an active treatment for advanced urothelial carcinoma. J Clin Oncol 2001;19:2527-33.
29. Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991;145:459-67.
30. Stöckle M, Meyenburg W, Wellek S, Voges G, Gertenbach U, Thüroff JW et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radikal cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992;148:302-7.
31. Otto T, Börgemann C, Krege S. Adjuvant chemotherapy in locally advanced bladder cancer (PT3/PN1-2.M0) - a phase III study. Eur Urol 2001;39(Suppl 5):147.
32. Sternberg CN, Donat SM, Bellmunt J, Millikan RE, Stadler W, de Mulder P et al. Chemotherapy for Bladder Cancer: Treatment Guidelines for Neoadjuvant Chemotherapy, Bladder Preservation, Adjuvant Chemotherapy, and Metastatic Cancer. Urol 2007;69(suppl.1A):62-79.
33. Sylvester R, Sternberg C. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer. What we do not know and why. Ann Oncol 2000;11:851-6.
34. Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17:3173-81.
35. Stadler WM, Hayden A, von der Maase H, Roychowdhury D, Dogliotti L, Seymour L et al. Long-term survival in Phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol 2002;7:153-7.
36. Bellmunt J, Albiol S. Chemotherapy for Metastatic and Unresectable Bladder Cancer. Semin Oncol 2007;34:135-44.
37. Sternberg CN. Current perspectives in muscle invasive bladder cancer. Eur J Cancer 2002;38:460-7.
38. Sternberg CN. Neoadjuvant and adjuvant chemotherapy of bladder cancer: is there a role? Ann Oncol 2002;13(suppl 4):273-9.
39. de Braud F, Maffezzini M, Vitale V, Bruzzi P, Gatta G, Hendry WF et al. Bladder cancer. Crit Rev Oncol Hematol 2002;41:89-106.
40. Sánchez-Carbayo M, Cordon-Cardo C. Molecular alterations associated with bladder cancer progression. Semin Oncol 2007;34:75-84.
41. Bellmunt J, De Witt R, Albiol S, Tabernero J, Albanell J, Baselga J. New drugs and new approaches in metastatic bladder cancer. Crit Rev Oncol Hematol 2003;47:195-206.
42. von der Maase H. Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev Anticancer Ther 2003;3:11-9.
43. Sánchez-Carbayo M. Recent advances in bladder cancer diagnostics. Clin Biochem 2004;37:562-71.
44. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel / cisplatin / gemcitabine (PCG) and gemcitabine / cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC 30987 / Intergroup study. J Clin Oncol 2007;25(18S);LBA5030.